Literature DB >> 33394111

Medical Interventions for Chylothorax and their Impacts on Need for Surgical Intervention and Admission Characteristics: A Multicenter, Retrospective Insight.

Rohit S Loomba1,2, Joshua Wong2, Megan Davis2, Sarah Kane2, Brian Heenan2, Juan S Farias3, Enrique G Villarreal4, Saul Flores5.   

Abstract

The incidence of chylothorax is reported from 1-9% in pediatric patients undergoing congenital heart surgery. Effective evidenced-based practice is limited for the management of post-operative chylothorax in the pediatric cardiac intensive care unit. The study characterizes the population of pediatric patients with cardiac surgery and chylothorax who eventually require pleurodesis and/or thoracic duct ligation; it also establishes objective data on the impact of various medical interventions. Data were obtained from the Pediatric Health Information System database from 2004-2015. Inclusion criteria for admissions for this study were pediatric admissions, cardiac diagnosis, cardiac surgery, and chylothorax. These data were then divided into two groups: those that did and did not require surgical intervention for chylothorax. Other data points obtained included congenital heart malformation, age, gender, length of stay, billed charges, and inpatient mortality. A total of 3503 pediatric admissions with cardiac surgery and subsequent chylothorax were included. Of these, 236 (9.4%) required surgical intervention for the chylothorax. The following cardiac diagnoses, cardiac surgeries, and comorbidities were associated with increased odds of surgical intervention: d-transposition, arterial switch, mitral valvuloplasty, acute kidney injury, need for dialysis, cardiac arrest, and extracorporeal membrane oxygenation. Statistically significant medical interventions which did have an impact were specific steroids (hydrocortisone, dexamethasone, methylprednisolone) and specific diuretics (furosemide). These were significantly associated with decreased length of stay and costs. Dexamethasone, methylprednisolone, and furosemide were associated with decreased odds for surgical intervention. These analyses offer objective data regarding the effects of interventions for chylothorax in pediatric cardiac surgery admissions. Results from this study seem to indicate that most post-operative chylothoraxes should improve with furosemide, a low-fat diet, and steroids.

Entities:  

Keywords:  Cardiac surgical procedure; Chylothorax; Congenital heart defects; Length of stay; Mortality; Pediatrics

Mesh:

Year:  2021        PMID: 33394111     DOI: 10.1007/s00246-020-02512-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  4 in total

1.  Successful treatment of congenital chylothorax with skimmed milk and long course octreotide.

Authors:  Tanushree Sahoo; Mukul Kumar Mangla; Amanpreet Sethi; Anu Thukral
Journal:  BMJ Case Rep       Date:  2018-12-03

2.  Risk factors for chylothorax and persistent serous effusions after congenital heart surgery.

Authors:  Anna Raatz; Martin Schöber; Robert Zant; Robert Cesnjevar; André Rüffer; Ariawan Purbojo; Sven Dittrich; Muhannad Alkassar
Journal:  Eur J Cardiothorac Surg       Date:  2019-12-01       Impact factor: 4.191

Review 3.  Report of a case of neonatal chylothorax that responded to long-term octreotide treatment, and review of the literature.

Authors:  Ufuk Çakır; Dilek Kahvecioğlu; Duran Yıldız; Serdar Alan; Ömer Erdeve; Begüm Atasay; Saadet Arsan
Journal:  Turk J Pediatr       Date:  2015 Mar-Apr       Impact factor: 0.552

4.  Incidence and Treatment of Chylothorax in Children Undergoing Corrective Surgery for Congenital Heart Diseases.

Authors:  Nicolle Martin Christofe; Cristiane Felix Ximenes Pessotti; Laércio Paiva; Ieda Biscegli Jatene
Journal:  Braz J Cardiovasc Surg       Date:  2017 Sep-Oct
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.